Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Margaret Macy

Concepts (237)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neuroblastoma
14
2026
174
3.090
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2026
1961
1.560
 Why?
Neoplasms
19
2026
2873
1.420
 Why?
Central Nervous System Neoplasms
3
2024
175
1.320
 Why?
Neoplasm Recurrence, Local
14
2026
1145
1.220
 Why?
Sarcoma, Ewing
3
2025
103
1.140
 Why?
Protein Kinase Inhibitors
7
2025
971
0.830
 Why?
Cyclin-Dependent Kinase 4
1
2024
53
0.830
 Why?
Cyclin-Dependent Kinase 6
1
2024
49
0.820
 Why?
Central Nervous System Diseases
1
2024
74
0.770
 Why?
Neoplasms, Second Primary
1
2024
101
0.750
 Why?
Glioma
5
2025
429
0.740
 Why?
Antineoplastic Agents
12
2026
2201
0.740
 Why?
Drug Resistance, Neoplasm
8
2026
881
0.730
 Why?
Piperazines
1
2024
378
0.700
 Why?
Antibodies, Monoclonal, Humanized
5
2022
990
0.690
 Why?
Glycolipids
1
2021
52
0.670
 Why?
Child
45
2026
22600
0.620
 Why?
Pyridines
1
2024
603
0.620
 Why?
Radiation Injuries
2
2019
149
0.610
 Why?
Indazoles
2
2022
82
0.590
 Why?
Bevacizumab
2
2019
168
0.580
 Why?
Brain Stem Neoplasms
2
2017
87
0.570
 Why?
Astrocytoma
2
2017
129
0.570
 Why?
Benzamides
2
2022
224
0.570
 Why?
Radiotherapy
1
2019
205
0.550
 Why?
Child, Preschool
28
2026
11790
0.550
 Why?
Brain Diseases
1
2019
152
0.540
 Why?
Chemoradiotherapy
2
2017
239
0.540
 Why?
Receptor Protein-Tyrosine Kinases
2
2022
230
0.530
 Why?
Angiogenesis Inhibitors
1
2019
238
0.520
 Why?
Adolescent
33
2026
22409
0.470
 Why?
3-Iodobenzylguanidine
3
2025
13
0.460
 Why?
Prognosis
14
2026
4312
0.450
 Why?
Gangliosides
2
2025
23
0.410
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2026
161
0.390
 Why?
Sarcoma
2
2015
203
0.390
 Why?
Brain Neoplasms
5
2022
1327
0.390
 Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2026
279
0.390
 Why?
Rhabdomyosarcoma
2
2025
64
0.350
 Why?
Sulfonamides
2
2026
579
0.340
 Why?
Piperidines
2
2025
219
0.340
 Why?
Quinazolines
2
2023
266
0.330
 Why?
Neoplasms, Germ Cell and Embryonal
1
2012
76
0.330
 Why?
Topoisomerase II Inhibitors
1
2010
26
0.330
 Why?
Biomarkers, Tumor
4
2022
1319
0.320
 Why?
Antineoplastic Agents, Immunological
2
2025
201
0.320
 Why?
Humans
53
2026
144667
0.320
 Why?
Maximum Tolerated Dose
6
2025
211
0.310
 Why?
Follow-Up Studies
10
2026
5414
0.310
 Why?
Survival Rate
8
2026
2089
0.310
 Why?
Antibodies, Monoclonal
7
2026
1505
0.300
 Why?
Glioblastoma
1
2012
353
0.280
 Why?
Young Adult
15
2026
14122
0.270
 Why?
Leukemia
1
2010
245
0.270
 Why?
DNA Damage
1
2010
430
0.260
 Why?
Male
31
2026
72431
0.250
 Why?
Infant
14
2026
10023
0.250
 Why?
Female
31
2026
78304
0.240
 Why?
Leukemia, Myeloid, Acute
3
2025
685
0.230
 Why?
Trastuzumab
1
2026
117
0.230
 Why?
Medical Oncology
2
2024
331
0.230
 Why?
Liver Neoplasms
1
2012
777
0.230
 Why?
Infratentorial Neoplasms
1
2026
71
0.230
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
293
0.220
 Why?
Gene Expression Profiling
1
2012
1766
0.220
 Why?
Camptothecin
2
2017
138
0.220
 Why?
Cyclin D
1
2024
8
0.220
 Why?
Cyclin-Dependent Kinases
1
2025
122
0.210
 Why?
Glycogen Synthase Kinase 3 beta
1
2024
72
0.210
 Why?
Dose-Response Relationship, Drug
5
2025
2019
0.210
 Why?
Ependymoma
1
2026
176
0.210
 Why?
TOR Serine-Threonine Kinases
3
2024
452
0.210
 Why?
Bone Neoplasms
2
2024
255
0.200
 Why?
Neoplasm Staging
3
2024
1465
0.200
 Why?
Carcinoma, Non-Small-Cell Lung
2
2023
1186
0.200
 Why?
Sirolimus
2
2016
280
0.190
 Why?
Osteosarcoma
1
2023
76
0.180
 Why?
Oncogene Proteins, Fusion
1
2024
211
0.180
 Why?
Pediatrics
2
2020
1121
0.180
 Why?
High-Throughput Nucleotide Sequencing
2
2023
552
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2024
435
0.180
 Why?
Topotecan
3
2026
17
0.170
 Why?
Adult
17
2026
40489
0.170
 Why?
Central Nervous System
1
2024
279
0.170
 Why?
Phosphatidylinositol 3-Kinases
1
2023
380
0.160
 Why?
Whole Genome Sequencing
1
2021
184
0.160
 Why?
Salvage Therapy
2
2019
164
0.160
 Why?
Necrosis
2
2019
243
0.160
 Why?
Receptor, IGF Type 1
2
2010
63
0.150
 Why?
Pyridazines
1
2020
57
0.150
 Why?
Lung Neoplasms
2
2023
2660
0.150
 Why?
Dexamethasone
2
2019
366
0.140
 Why?
Etoposide
3
2017
168
0.140
 Why?
Imidazoles
1
2020
246
0.140
 Why?
Combined Modality Therapy
2
2020
1268
0.140
 Why?
Lymphoma
1
2019
233
0.130
 Why?
Taxoids
1
2018
116
0.130
 Why?
B7-H1 Antigen
1
2019
242
0.130
 Why?
Induction Chemotherapy
1
2017
87
0.130
 Why?
Heterocyclic Compounds
1
2017
23
0.130
 Why?
Antineoplastic Agents, Phytogenic
1
2018
176
0.130
 Why?
Incidence
1
2024
2892
0.120
 Why?
Cetuximab
1
2017
111
0.120
 Why?
Glucocorticoids
2
2019
528
0.120
 Why?
Azacitidine
1
2017
157
0.120
 Why?
Cytarabine
3
2025
66
0.120
 Why?
Hematopoietic Stem Cell Transplantation
1
2022
677
0.120
 Why?
Clinical Trials as Topic
3
2025
1056
0.120
 Why?
Myelodysplastic Syndromes
1
2017
147
0.110
 Why?
Retrospective Studies
6
2026
17149
0.110
 Why?
Cyclophosphamide
2
2026
265
0.110
 Why?
Feasibility Studies
1
2019
1103
0.110
 Why?
Treatment Outcome
9
2025
11735
0.110
 Why?
Thyroxine
1
2014
65
0.100
 Why?
Hypothyroidism
1
2014
67
0.100
 Why?
Pilot Projects
1
2019
1886
0.100
 Why?
Melanoma
1
2019
757
0.090
 Why?
Arsenicals
1
2013
28
0.090
 Why?
Oxides
1
2013
49
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
431
0.090
 Why?
Organoplatinum Compounds
1
2012
66
0.090
 Why?
Leucovorin
1
2012
100
0.090
 Why?
DNA Methylation
1
2017
664
0.090
 Why?
In Situ Hybridization, Fluorescence
2
2012
323
0.090
 Why?
Animals
4
2021
37948
0.090
 Why?
Consensus
2
2025
475
0.090
 Why?
Fluorouracil
1
2012
234
0.090
 Why?
Real-Time Polymerase Chain Reaction
1
2012
339
0.090
 Why?
Spinal Cord
1
2014
384
0.080
 Why?
Magnetic Resonance Imaging
3
2019
3888
0.080
 Why?
HL-60 Cells
1
2010
29
0.080
 Why?
Inhibitory Concentration 50
1
2010
90
0.080
 Why?
Oligonucleotide Array Sequence Analysis
1
2012
751
0.080
 Why?
Antimetabolites, Antineoplastic
1
2010
105
0.080
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2012
973
0.080
 Why?
Pyrazoles
2
2025
512
0.080
 Why?
Drug Synergism
1
2010
352
0.080
 Why?
Pons
1
2009
33
0.080
 Why?
Brain
2
2014
2934
0.070
 Why?
Methotrexate
1
2010
231
0.070
 Why?
Vascular Endothelial Growth Factor A
2
2009
550
0.070
 Why?
Polyethylene Glycols
1
2014
652
0.070
 Why?
Infant, Newborn
3
2022
6399
0.070
 Why?
Recurrence
2
2010
1136
0.070
 Why?
Molecular Targeted Therapy
2
2022
437
0.070
 Why?
Chemistry, Pharmaceutical
1
2008
112
0.070
 Why?
Doxorubicin
1
2010
398
0.070
 Why?
Drug Design
1
2008
176
0.070
 Why?
Acute Disease
1
2010
1029
0.070
 Why?
Cell Cycle
1
2010
595
0.070
 Why?
Cell Survival
1
2010
1092
0.060
 Why?
Pyrimidines
2
2023
519
0.060
 Why?
MAP Kinase Signaling System
1
2008
306
0.060
 Why?
Genomics
2
2022
831
0.060
 Why?
Injections, Spinal
1
2026
120
0.060
 Why?
Risk Assessment
1
2015
3729
0.060
 Why?
Cohort Studies
3
2022
5957
0.060
 Why?
Everolimus
1
2025
112
0.050
 Why?
Proto-Oncogene Protein c-fli-1
1
2024
30
0.050
 Why?
RNA-Binding Protein EWS
1
2024
31
0.050
 Why?
Phenylurea Compounds
1
2025
113
0.050
 Why?
United States Food and Drug Administration
1
2025
205
0.050
 Why?
Disease Progression
1
2012
2847
0.050
 Why?
Europe
1
2025
419
0.050
 Why?
Mice
1
2021
18261
0.050
 Why?
RNA, Messenger
1
2012
2815
0.050
 Why?
Immunoconjugates
1
2025
138
0.050
 Why?
Vincristine
1
2024
140
0.050
 Why?
Quinolines
1
2025
192
0.050
 Why?
Lactams
1
2023
28
0.050
 Why?
Radioisotopes
1
2023
37
0.050
 Why?
Infusions, Intravenous
1
2024
422
0.050
 Why?
Cell Proliferation
1
2010
2489
0.050
 Why?
Lactams, Macrocyclic
1
2023
51
0.050
 Why?
Magnesium
1
2023
155
0.050
 Why?
National Cancer Institute (U.S.)
1
2022
52
0.050
 Why?
Gene Amplification
1
2023
119
0.050
 Why?
Aminopyridines
1
2023
129
0.050
 Why?
Apoptosis
1
2010
2397
0.040
 Why?
Oncogenes
1
2022
118
0.040
 Why?
Proto-Oncogene Proteins c-myc
1
2023
167
0.040
 Why?
Microtubule-Associated Proteins
1
2022
195
0.040
 Why?
Models, Biological
1
2008
1811
0.040
 Why?
Drug and Narcotic Control
1
2020
24
0.040
 Why?
Carcinogenesis
1
2022
227
0.040
 Why?
Drug Evaluation, Preclinical
1
2020
195
0.040
 Why?
Immunologic Factors
1
2022
259
0.040
 Why?
United States
3
2025
16018
0.040
 Why?
Fatigue
1
2022
363
0.040
 Why?
Proto-Oncogene Proteins
1
2022
619
0.040
 Why?
Base Sequence
1
2022
2177
0.040
 Why?
Disease Susceptibility
1
2020
342
0.040
 Why?
Retreatment
1
2018
77
0.030
 Why?
Isotretinoin
1
2018
26
0.030
 Why?
Metabolic Clearance Rate
1
2018
115
0.030
 Why?
Hematologic Diseases
1
2018
66
0.030
 Why?
Daunorubicin
1
2017
25
0.030
 Why?
Azepines
1
2018
106
0.030
 Why?
Precision Medicine
1
2021
454
0.030
 Why?
Benzylamines
1
2017
43
0.030
 Why?
Blepharoptosis
1
1997
13
0.030
 Why?
Genes, Dominant
1
1997
100
0.030
 Why?
Disease-Free Survival
1
2019
768
0.030
 Why?
Treatment Failure
1
2018
365
0.030
 Why?
Immunotherapy
1
2022
662
0.030
 Why?
Chromosomes, Human, Pair 1
1
1997
79
0.030
 Why?
Drug Hypersensitivity
1
2018
89
0.030
 Why?
Receptors, CXCR4
1
2017
91
0.030
 Why?
Gastrointestinal Diseases
1
2018
217
0.030
 Why?
Kaplan-Meier Estimate
1
2018
967
0.030
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.030
 Why?
Drug Monitoring
1
2018
396
0.030
 Why?
SEER Program
1
2015
226
0.030
 Why?
Age Factors
1
2020
3329
0.020
 Why?
Genetic Predisposition to Disease
1
2021
2350
0.020
 Why?
Promoter Regions, Genetic
1
2017
1246
0.020
 Why?
Epigenesis, Genetic
1
2017
669
0.020
 Why?
Analysis of Variance
1
2015
1301
0.020
 Why?
Neoplasm Grading
1
2013
310
0.020
 Why?
Prevalence
1
2019
2839
0.020
 Why?
Mutation
1
2023
4081
0.020
 Why?
Radiography
1
2014
848
0.020
 Why?
Signal Transduction
1
2024
5185
0.020
 Why?
Prospective Studies
1
2022
7994
0.020
 Why?
Fatal Outcome
1
2009
305
0.020
 Why?
Tomography, X-Ray Computed
1
2018
2754
0.020
 Why?
Radiosurgery
1
2009
398
0.010
 Why?
Aged
1
2024
25955
0.010
 Why?
Middle Aged
1
2024
35971
0.010
 Why?
Lod Score
1
1997
62
0.010
 Why?
Quality of Life
1
2009
3183
0.010
 Why?
Genetic Markers
1
1997
332
0.010
 Why?
Recombination, Genetic
1
1997
205
0.010
 Why?
Chromosome Mapping
1
1997
507
0.010
 Why?
Pedigree
1
1997
515
0.010
 Why?
Genotype
1
1997
1847
0.010
 Why?
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (237) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)